Table 1.

Phase III studies in advanced gastric cancer.

Regimen	No. pts.	Antitumor activity		Survival		Author (year)
		Response rate	P value	Median	P value
FAMTX	105	41%	< .001	10.5 mo	.004	Wils4 (1991)
FAM	103	9%		7.3 mo
FAMTX	30	33%	NS	7.3 mo	NS	Kelsen5 (1992)
EAP	30	20%		6.1 mo
FP	103	51%	< .01	9.2 mo	NS	Kim7 (1993)
FAM	98	25%		7.3 mo
5F - U	94	26%		7.7 mo
ECF	126	45% (n=111)	< .001	8.9 mo	< .001	Webb8 (1997)
FAMTX	130	21% (n=108)		5.7 mo
FAMTX	133	12%	NS	6.7 mo	NS	Vanhoefer9 (2000)
FP	134	20%		7.2 mo
ELF	132	9%		7.2 mo
DCF	221	37%	.0106	9.2 mo	.0201	Moiseyenko10 (2005)
FP	224	25%		8.6 mo
IF	170	32%	NS	9.0 mo	NSa	Dank11 (2005)
FP	163	26%		8.7 mo
FLO	112	34%	NS	–	Not maturedb	Al-Batran12 (2006)
FLP	106	25%		–
ECF	263	38%	NS v ( s. ECF)	9.9 mo	Noninferiority of X over Fand O over C was demonstrated	Cunningham13 (2006)
EOF	245	40%		9.3 mo
ECX	250	41%		9.9 mo
EOX	144	47%		11.2 mo
XP	139	41% (n=160)	.03	10.5 mo	NSc	Kang14 (2006)
FP	137	29% (n=156)		9.3 mo

Abbreviations: FAMTX = 5-FU (5-fluorouracil)/doxorubicin/methotrexate; FAM = 5-FU/doxorubicin/mitomycin C; EAP = etoposide/doxorubicin/cisplatin; FP = 5-FU/cisplatin; ECF = epirubicin/cisplatin/5-FU; ELF = etoposide/leucovorin/5-FU; DCF = docetaxel/cisplatin/5-FU; IF = irinotecan/leucovorin/5-FU; FLO = 5-FU/leucovorin/oxaliplatin; FLP = 5-FU/leucovorin/cisplatin; EOF = epirubicin/oxaliplatin/5-FU; ECX = epirubicin/cisplatin/capecitabine; EOX = epirubicin/oxaliplatin/capecitabine; XP = capecitabine/cisplatin; NS = not significant.

a Primary end point was superiority in time to progression: 5.0 months for IF, 4.2 months for FP; NS.

b Primary end point was superiority in time to progression: 5.7 months for FLO, 3.8 months for FLP; NS.

c Primary end point was noninferiority in progression-free survival: 5.6 months for XP, 5.0 months for FP; noninferiority was demonstrated.